Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hypo-IMRT with Temozolomide and Bevacizumab for Newly Diagnosed GBM
NCT01209442Phase 2Completed
- Sponsor
- University of Colorado Denver
- Start
- Sep 2010
- Primary completion
- Sep 2014
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of bevacizumab in glioblastoma (GBM), sponsored by University of Colorado Denver. Started Sep 2010; status: completed.
02
Drugs
bevacizumab
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT01209442.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01209442.